PD-L1 t-haNK Clinical Trials
2 recruitingBiologic
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Head and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Cancer+1 more
Glenn J. Hanna25 enrolled2 locationsNCT06239220
Recruiting
Phase 2
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Glioblastoma
ImmunityBio, Inc.34 enrolled4 locationsNCT06061809